Investigate the autoantibody response to a novel drug (GSK2862277) and their effect on TNFR1 activation
Study code
CBR109
Lead researcher
Dr Andrew Bayliffe
Study type
Samples and data
Institution or company
GlaxoSmithKline
Researcher type
Commercial
Speciality area
Infection
Recruitment Site
Cambridge
Summary
The aim of the study is to explore the function of human anti-immunogloblin autoantibody responses and why they are present in humans. Furthermore; through the study team aims to identify subjects with anti-Vh autoantibody responses that also bind to GSK2862277 with the possibility of confirming the relationship of pre-existing anti-drug antibodies (ADAs) and propensity for adverse events in humans dosed with GSK2862277.
Participation: 4000 serum samples from the Cambridge BioResource volunteers were provided for this study.
Organisation: This study is organised by Dr Andrew Bayliffe from GlaxoSmithKline.